Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of Glofitamab in Patients with R/R DLBCL in Real Life Setting - a Retrospective Study

Ronit Gurion, Dmitri Guz, Meirav Kedmi, Chava Perry, Irit Avivi Mazza, Netanel A. Horowitz, Uri Abadi, Anat Gafter-Gvili, Pia Raanani, Neta Goldschmidt, Boaz Nachmias, Shlomzion Aumann

Blood (2023) 142 (Supplement 1): 5170.

https://doi.org/10.1182/blood-2023-186033

Published: 2023

Journal Articles

Odronextamab Demonstrates Durable Complete Responses in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Progressing after CAR-T Therapy: Outcomes from the ELM-1 Study

Jennifer L. Crombie, Matthew Matasar, Max S. Topp, John N. Allan, Jeffrey A. Barnes, Jon E. Arnason, Jean-Marie Michot, Neta Goldschmidt, Susan M. O'Brien, Uri Abadi, Irit Avivi Mazza, Jessica Cai, Dina M. Flink, Min Zhu, Jurriaan Brouwer-Visser, Hesham Mohamed, Aafia Chaudhry, Srikanth Ambati, Steve M Ansell

Blood (2023) 142 (Supplement 1): 4461.

https://doi.org/10.1182/blood-2023-181602

Published: 2023

Journal Articles

Deep Proteomic Analysis Reveals Shared Terminal Mechanisms for Familial Hemophagocytic Lymphohistiocytosis and Lymphoma-Associated Hyperinflammation

Adi Zoref-Lorenz, Uri Abadi, Ronit Gurion, Alexander Osnis, Joanne Yacobovich, Yehudit Birger, Galit Berger Pinto, Pia Raanani, Arnon Nagler, Shai Dulberg, Asaf Madi, Gilad Itchaki, Martin H. Ellis, Shai Izraeli, Michael B. Jordan

Blood (2023) 142 (Supplement 1): 677.

https://doi.org/10.1182/blood-2023-189849

Published: 2023

Journal Articles

The Optimized HLH Inflammatory Index Is Associated with a Higher Stage of Lymphoma, but an Unexpected High Mortality Associated with Inflammation

Blood (2022) 140 (Supplement 1): 8326–8328.

https://doi.org/10.1182/blood-2022-170790

Published: 2022

Journal Articles

Obinutuzumab Versus Rituximab Based First-Line Chemoimmunotherapy for Follicular Lymphoma - a Real-World Multicenter Retrospective Cohort Study

Tamar Berger, Tzippy Shochat, Shlomzion Aumann, Boaz Nachmias, Neta Goldschmidt, Nurit Horesh, Reut Harel, Ariel Aviv, Ella Shmerts, Uri Abadi, Pia Raanani, Anat Gafter-Gvili, Ronit Gurion

Blood (2022) 140 (Supplement 1): 11947–11948.

https://doi.org/10.1182/blood-2022-159881

Published: 2022

Journal Articles

Mosunetuzumab Monotherapy Continues to Demonstrate Promising Efficacy and Durable Complete Responses in Elderly/Unfit Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Adam J. Olszewski, Abraham Avigdor, Sunil Babu, Itai Levi, Herbert Eradat, Uri Abadi, Houston Holmes, Matthew McKinney, Dariusz Woszczyk, Krzysztof Giannopoulos, Wojciech Jurczak, Diana Dunshee, Annie Yang, Mingzhu Zhou, Naseer Qayum, Gila Sellam, Netanel A. Horowitz

Blood (2022) 140 (Supplement 1): 1778–1780.

https://doi.org/10.1182/blood-2022-157768

Published: 2022

Journal Articles

Real-World Efficacy of Venetoclax-Based Regimens in Patients with Chronic Lymphocytic Leukemia in Israel: A Multicenter Prospective Study

Yair Herishanu, Neta Goldschmidt, Gilad Itchaki, Itai Levi, Ariel Aviv, Riva Fineman, Najib Dally, Tamar Tadmor, Rosa Ruchlemer, Uri Abadi, Lev Shvidel, Andrei Braester, Raanan Cohen, Neta Frankel, Keren Ofek, Jenia Berelovich, Moshe Grunspan, Ohad Benjamini

Blood (2021) 138 (Supplement 1): 3727.

https://doi.org/10.1182/blood-2021-146504

Published: 2021

Journal Articles

Single-Agent Mosunetuzumab Is a Promising Safe and Efficacious Chemotherapy-Free Regimen for Elderly/Unfit Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Adam J Olszewski, MD, Abraham Avigdor, MD, Sunil Babu, Itai Levi, MD, Uri Abadi, Houston Holmes, Matthew McKinney, Ron McCord, Yuying Xie, Cindy Chen, Kati Sarouei, Naseer Qayum, Carol O'Hear, Gila Sellam, Herbert Eradat

Blood (2020) 136 (Supplement 1): 43–45.

https://doi.org/10.1182/blood-2020-136255

Published: 2020

Journal Articles

Outcome of Relapsed DLBCL Patients, Treated with Polatuzumab-BR or Polatuzumab-R: Real Life Data

Yafit Segman, MD, Elena Ribakovsky, MD, Abraham Avigdor, MD, Vladimir Vainstein, MD, Neta Goldschmidt, MD, Shimrit Ringelstein Harlev, MD, Odit Gutwein, Uri Abadi, MD, Anatoly Nemets, MD, Orit Sofer, Najib Dally, MD, Kalman Filanovsky, MD, Merav Leiba, MD, Nadav Sarid, MD, Noam Benyamini, MD, Yair Herishanu, MD, Ron Ram, MD, Chava Perry, MD PhD, Irit Avivi

Blood (2019) 134 (Supplement_1): 5321.

https://doi.org/10.1182/blood-2019-124164

Published: 2019

Journal Articles

Can We Improve the Predictive Value of Interim PET/CT Using a New Prognostic Model for Advanced Hodgkin Lymphoma?

Eldad J. Dann, MD, Osnat Bairey, MD, Rachel Bar-Shalom, MD, Tanya Mashiach, MSc, Elinor Barzilai, BSc, Abraham Korenberg, MD, Luiza Akria, MD, Tamar Tadmor, MD, Kalman Filanovsky, MD, Uri Abadi, MD, Olga Kagna, MD, Rosa Ruchlemer, MD, Neta Goldschmidt, MD, Netanel A. Horowitz, MD, David Lavie, MD, Dina Ben-Yehuda, MD, Ofer Shpilberg, MD, Ora B. Paltiel, MDM, MSc

Blood (2016) 128 (22): 3001.

https://doi.org/10.1182/blood.V128.22.3001.3001

Published: 2016

Journal Articles

Analysis of Final Data from the Multinational, Non-Interventional, Observational Emmos Study (NCT01241396) in Patients (Pts) with Multiple Myeloma (MM) in Real-World Clinical Practice

Blood (2015) 126 (23): 3034.

https://doi.org/10.1182/blood.V126.23.3034.3034

Published: 2015

Journal Articles

Tailored Therapy in Hodgkin Lymphoma, Based on Predefined Risk Factors and Early Interim PET/CT: Israeli H2 Study

Eldad J Dann, MD, Osnat Bairey, MD, Rachel Bar-Shalom, MD, Elinor Sabbag, BSc., Marina Izak, MD, Abraham Korenberg, MD, Luiza Akria, MD, Dina Attias, MD, Kalman Filanovsky, MD, Uri Abadi, MD, Rosa Ruchlemer, MD, Roxolyana Abdah-Bortnyak, MD, Neta Goldschmidt, MD, Ron Epelbaum, MD, Netanel Horowitz, David Lavie, MD, Dina Ben Yehuda, MD, Ofer Shpilberg, MD, Ora B. Paltiel, MDM, MSc

Blood (2014) 124 (21): 4409.

https://doi.org/10.1182/blood.V124.21.4409.4409

Published: 2014

NARROW

Efficacy and Safety of Glofitamab in Patients with R/R DLBCL in Real Life Setting - a Retrospective Study

Odronextamab Demonstrates Durable Complete Responses in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Progressing after CAR-T Therapy: Outcomes from the ELM-1 Study

Deep Proteomic Analysis Reveals Shared Terminal Mechanisms for Familial Hemophagocytic Lymphohistiocytosis and Lymphoma-Associated Hyperinflammation

The Optimized HLH Inflammatory Index Is Associated with a Higher Stage of Lymphoma, but an Unexpected High Mortality Associated with Inflammation

Obinutuzumab Versus Rituximab Based First-Line Chemoimmunotherapy for Follicular Lymphoma - a Real-World Multicenter Retrospective Cohort Study

Mosunetuzumab Monotherapy Continues to Demonstrate Promising Efficacy and Durable Complete Responses in Elderly/Unfit Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Real-World Efficacy of Venetoclax-Based Regimens in Patients with Chronic Lymphocytic Leukemia in Israel: A Multicenter Prospective Study

Single-Agent Mosunetuzumab Is a Promising Safe and Efficacious Chemotherapy-Free Regimen for Elderly/Unfit Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Outcome of Relapsed DLBCL Patients, Treated with Polatuzumab-BR or Polatuzumab-R: Real Life Data

Can We Improve the Predictive Value of Interim PET/CT Using a New Prognostic Model for Advanced Hodgkin Lymphoma?

Analysis of Final Data from the Multinational, Non-Interventional, Observational Emmos Study (NCT01241396) in Patients (Pts) with Multiple Myeloma (MM) in Real-World Clinical Practice

Tailored Therapy in Hodgkin Lymphoma, Based on Predefined Risk Factors and Early Interim PET/CT: Israeli H2 Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only